An estimated seven to ten million people worldwide are living with Parkinson's disease (PD). More than half of PD patients develop progressive disease showing signs of dementia similar to Alzheimer's disease. A research team has discovered that non-inheritable PD may be caused by functional changes in the immune regulating gene Interferon-beta. Show More Summary
More and more data from preclinical and clinical studies strengthen the hypothesis that immune system-mediated actions contribute to and drive pathogenesis in Alzheimer’s disease. New insights suggest that A? indeed induces a strongShow More Summary
"This study has let us characterize the parameters of decline in people who will eventually develop Alzheimer's, which means we can better identify both benign symptoms and those that warrant particular attention." - Sylvie Bellevil...
By +Alzheimer's Reading Room A naturally occurring compound found in dark chocolate and red wine might be able to slow or stop the progress of Alzheimer’s disease. A compound in red wine, resveratrol, that appears to have anti-aging effects could become a new way to treat Alzheimer's disease, early research suggests. Show More Summary
A new study has found tantalizing evidence that a highly concentrated form of a compound found in red wine and dark chocolate might be able to slow the progression of Alzheimer’s disease.But it’s likely that it’s because the compound is tricking the body into acting as if it’s not eating at all.Read full article >>
While not proving that dementia can be “caught”, the explosive findings provide the first evidence of its transmission in humans via microscopic protein molecules. These days Alzheimer’s is recognised as a progressive neurological condition that mostly arises in the old. Thanks to new medical techniques cancer breakthroughs are improving patients’ chances all the time. Britain
MRI scans and other tools to detect and diagnose dementia are helpful but not definitive. A new report evaluates how well different types of brain imaging tests work to detect Alzheimer's and predict how the disease will progress.The...Show More Summary
People with Alzheimer’s disease have fat deposits in the brain, which may help to explain the progression of the disease. Researchers affiliated with the University of Montreal Hospital Research Centre (CRCHUM) have discovered accumulations of fat droplets in the brain of patients who died from the disease and have identified the nature of the fat. This […]
Right now, there is only symptomatic treatment for Alzheimer’s disease, which does not stall the progress of the disease. Nor does this approach provide insights on the causes. But if findings from recent research studies are to be weighed upon, this is about to change. Alzheimer’s disease (AD) is a curse, both for the person […]
A new meta-analysis of 323 studies looks at 93 possible factors associated with the risk of developing Alzheimer’s disease (AD). AD is a neurodegenerative disorder affecting the entire brain that causes a slowly progressive dementia over years. Dementia is a generic term for a chronic disorder of memory and cognition. AD is a specific disease [...]
In today's Mayo Clinic Minute with Vivien Williams: Alzheimer's disease progresses faster in women than men, gender differences in concussion symptoms and time is of the essence when it comes to treating strokes. Click here for more on the Alzheimer's study, here for research on concussions and here for more on strokes. Show More Summary
A protein involved in the progression of Alzheimer's disease also has properties that could be helpful for human health, a research study has found. The discovery helps researchers better understand the complicated brain chemistry behind the development of Alzheimer's disease.
Pharmaceutical researchers on Wednesday presented new data from the clinical trials of three drugs that, the scientists said, show promise for slowing the progression of Alzheimer’s disease.Researchers presented new analyses of research data on drugs produced by Eli Lilly, Roche and Biogen. Show More Summary
I experienced the worst and best customer service experiences of my life from competing companies on the same day a few years ago. My widowed father's Alzheimer's disease had progressed to the point where he could no longer remain in an independent living apartment in his over-60 community. Show More Summary
Above, Dr. Matthew Norton, head of policy at Alzheimer’s Research UK, discusses the new drug. Scientists appear to have made a breakthrough in the battle against Alzheimer’s disease after announcing test results for a drug that appears...Show More Summary
A study sheds light on the influences of genetics on why some type 2 diabetics are at high risk for developing Alzheimer’s disease. While previous studies strongly suggested a causative role of diabetes in the onset and progression of Alzheimer’s disease dementia, the specific mechanistic interactions connecting diabetes and Alzheimer’s disease had not been previously described.
More than 4,000 scientists from around the world will gather in Washington this week to share the latest findings and ideas on Alzheimer’s disease, with some saying that the odds of finding effective treatments look promising even as an aging society increases the urgency of finding a cure.Read full article >>
Dementia is characterized by a progressive and debilitating decline in cognition, function and behavior. Its numbers are staggering: according to the World Health Organization, the total number of people with dementia worldwide in 2010 was estimated at 35.6 million and predicted to nearly double every 20 years, to 65.7 million in 2030 and 115.4 million […]
The amyloid cascade hypothesis of Alzheimer's disease (AD) posits that sticky aggregations or plaques of amyloid-beta peptides accumulate over time in the brain, triggering a series of events that ultimately result in the full-blown neurodegenerative disorder. Show More Summary
UC San Diego School of Medicine researchers report that the amyloid cascade hypothesis, long believed to describe the pathology of Alzheimer's disease, is not a fixed and invariable sequence of events. Rather, early indicators or biomarkers of the neurodegenerative condition vary by individual, making preclinical diagnoses more challenging.